SCINAI IMMUNOTHERAPEUTICS UPDATES INVESTOR PRESENTATION
Ticker: SCNI · Form: 6-K · Filed: Jan 9, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Jan 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: investor-presentation, corporate-update, 6-K
TL;DR
**SCNI just dropped an updated investor presentation, check it for the latest company info.**
AI Summary
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) filed a 6-K on January 9, 2024, to provide an updated corporate presentation for January 2024. This presentation, furnished as Exhibit 99.1, offers current information about the company's business. For investors, this matters because it provides the latest official overview of Scinai's strategy and pipeline, which could influence their perception of the stock's future potential and valuation.
Why It Matters
This filing provides investors with the most recent official overview of Scinai Immunotherapeutics' business, which can help them make informed decisions about their investment.
Risk Assessment
Risk Level: low — This filing is purely informational, providing an updated corporate presentation without indicating any immediate financial or operational risks.
Analyst Insight
A smart investor would review the 'Scinai Immunotherapeutics Presentation dated January 2024' (Exhibit 99.1) to understand the company's latest strategic direction, pipeline updates, and financial overview, then compare it to previous presentations and company filings to identify any significant changes or new developments.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — the registrant filing the 6-K
- Amir Reichman (person) — Chief Executive Officer who signed the filing
- January 9, 2024 (date) — date of the 6-K filing
- 001-37353 (other) — Commission File Number for Scinai Immunotherapeutics Ltd.
FAQ
What is the purpose of Scinai Immunotherapeutics Ltd.'s 6-K filing dated January 9, 2024?
The purpose of Scinai Immunotherapeutics Ltd.'s 6-K filing is to make available an updated presentation about its business, furnished as Exhibit 99.1 and incorporated by reference.
Who signed the 6-K filing on behalf of Scinai Immunotherapeutics Ltd.?
The 6-K filing was signed by Amir Reichman, the Chief Executive Officer of Scinai Immunotherapeutics Ltd., on January 9, 2024.
What is the exhibit number for the updated presentation mentioned in the 6-K filing?
The updated presentation is furnished as Exhibit 99.1, titled 'Scinai Immunotherapeutics Presentation dated January 2024'.
What was the former name of Scinai Immunotherapeutics Ltd.?
According to the filing, the former conformed name of Scinai Immunotherapeutics Ltd. was BiondVax Pharmaceuticals Ltd., with a name change date of 20140624.
What is the Commission File Number for Scinai Immunotherapeutics Ltd.?
The Commission File Number for Scinai Immunotherapeutics Ltd. is 001-37353.
Filing Stats: 244 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-01-09 08:45:21
Filing Documents
- ea191375-6k_scinaiimmun.htm (6-K) — 11KB
- ea191375ex99-1_scinaiimmun.htm (EX-99.1) — 48KB
- ex99-1_001.jpg (GRAPHIC) — 119KB
- ex99-1_002.jpg (GRAPHIC) — 296KB
- ex99-1_003.jpg (GRAPHIC) — 134KB
- ex99-1_004.jpg (GRAPHIC) — 163KB
- ex99-1_005.jpg (GRAPHIC) — 209KB
- ex99-1_006.jpg (GRAPHIC) — 237KB
- ex99-1_007.jpg (GRAPHIC) — 179KB
- ex99-1_008.jpg (GRAPHIC) — 141KB
- ex99-1_009.jpg (GRAPHIC) — 265KB
- ex99-1_010.jpg (GRAPHIC) — 184KB
- ex99-1_011.jpg (GRAPHIC) — 200KB
- ex99-1_012.jpg (GRAPHIC) — 142KB
- ex99-1_013.jpg (GRAPHIC) — 89KB
- ex99-1_014.jpg (GRAPHIC) — 254KB
- ex99-1_015.jpg (GRAPHIC) — 113KB
- ex99-1_016.jpg (GRAPHIC) — 232KB
- ex99-1_017.jpg (GRAPHIC) — 176KB
- ex99-1_018.jpg (GRAPHIC) — 346KB
- ex99-1_019.jpg (GRAPHIC) — 134KB
- ex99-1_020.jpg (GRAPHIC) — 280KB
- ex99-1_021.jpg (GRAPHIC) — 110KB
- ex99-1_022.jpg (GRAPHIC) — 176KB
- ex99-1_023.jpg (GRAPHIC) — 181KB
- ex99-1_024.jpg (GRAPHIC) — 188KB
- ex99-1_025.jpg (GRAPHIC) — 232KB
- ex99-1_026.jpg (GRAPHIC) — 119KB
- ex99-1_027.jpg (GRAPHIC) — 139KB
- ex99-1_028.jpg (GRAPHIC) — 103KB
- ex99-1_029.jpg (GRAPHIC) — 247KB
- ex99-1_030.jpg (GRAPHIC) — 245KB
- ex99-1_031.jpg (GRAPHIC) — 141KB
- ex99-1_032.jpg (GRAPHIC) — 139KB
- ex99-1_033.jpg (GRAPHIC) — 137KB
- 0001213900-24-002051.txt ( ) — 8396KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: January 9, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 3